Local view for "http://purl.org/linkedpolitics/eu/plenary/2011-02-15-Speech-2-593-250"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20110215.29.2-593-250"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
"It is essential to protect the pharmaceutical supply chain against the entry of falsified medicinal products for the sake of the general public and companies that operate correctly and responsibly. The directive being examined by Parliament must therefore be supported wholeheartedly, since it introduces procedures and obligations that I hope can lead to concrete and effective results. In particular, I would like to underline the importance of certain obligations placed on a range of actors involved in the supply chain, from distributors to wholesalers, and, above all, the introduction of ‘safety features’ on prescription medicinal products with the aim of assuring consumers of the integrity of the manufacturing and supply chain. Stricter rules on inspections, on the traceability of the substances contained in medicinal products, as well as on online sales, are further measures that I think will curb the trade in falsified medicinal products. It should be noted, however, that the compromise text establishes that there will be regular inspections at production sites in third countries, but that they will be carried out by the authorities of the third country in question. It would have been better if they were to be performed by the authorities of the countries to which the medicinal products are destined, because the main threat of falsification comes precisely from third countries."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples